GLPG0634 Shows Selective Inhibition of JAK1 and Maintained JAK-STAT Suppression in Healthy Volunteers

被引：0
|
作者：
Vanhoutte, Frederic [1 ]
Galien, Rene [2 ]
Vets, Eva [3 ]
Namour, Florence [2 ]
Vayssierre, Beatrice [2 ]
Van Rompaey, Luc [1 ]
Smets, Bart [1 ]
Brys, Reginald [1 ]
Wigerinck, Piet [1 ]
van 't Klooster, Gerben [1 ]
机构：
[1] Galapagos NV, Mechelen, Belgium
[2] Galapagos SASU, Romainville, France
[3] SGS, Antwerp, Belgium
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2210
引用
收藏
页码：S862 / S863
页数：2
相关论文
共 50 条
  • [41] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE AS MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
    Kavanaugh, A.
    Ponce, L.
    Cseuz, R.
    Reshetko, O.
    Stanislavchuk, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 247 - 247
  • [42] THE EFFECT OF FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR ON PATIENT-REPORTED OUTCOMES: RESULTS FROM TWO 24-WEEK PHASE 2B DOSE RANGING STUDIES
    Genovese, M.
    Westhovens, R.
    Kavanaugh, A.
    Meuleners, L.
    Van der Aa, A.
    Harrison, P.
    Tasset, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 244 - 244
  • [43] Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor
    Vermeire, S.
    De Hertogh, G.
    Chen, G.
    French, D.
    Huntzicker, E.
    Van der Aa, A.
    Van Kaem, T.
    Harrison, P.
    Tasset, C.
    Galien, R.
    Pan, Y.
    Feagan, B.
    Sandborn, W.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S20 - S21
  • [44] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
    Westhovens, R.
    Alten, R.
    Pavlova, D.
    Sosa, F. E. Enriquez
    Mazur, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 142 - 142
  • [45] FILGOTINIB (GLPG0634, GS-6034), A JAK-1 SELECTIVE INHIBITOR, SIGNIFICANTLY REDUCES GUT TISSUE PSTAT3 IN CROHN'S DISEASE PATIENTS
    Sandborn, William J.
    Feagan, Brian G.
    De Hertogh, Gert
    Chen, Guang
    French, Dorothy M.
    Huntzicker, Erik G.
    Van der Aa, Annegret
    Van Kaem, Tim
    Harrison, Pille
    Tasset, Chantal T.
    Galien, Rene
    Pan, Yang
    Vermeire, Severine
    GASTROENTEROLOGY, 2017, 152 (05) : S602 - S602
  • [46] DEVELOPMENT OF A JAK3 SPECIFIC INHIBITOR CLINICAL CANDIDATE: FUNCTIONAL DIFFERENTIATION OF JAK3 SELECTIVE INHIBITION OVER PAN-JAK OR JAK1 SELECTIVE INHIBITION
    Telliez, J. -B.
    Wang, L.
    Jussif, J.
    Lin, T. H.
    Li, L.
    Moy, E.
    Li, W.
    Zhao, Y.
    Crouse, K.
    Symanowicz, P.
    Hegen, M.
    Banker, M. E.
    Vincent, F.
    Clark, J. D.
    Thorarensen, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 114 - 115
  • [47] Population pharmacokinetic/pharmacodynamic modeling of H018, a selective JAK1 inhibitor, in healthy Chinese volunteers
    Qu, Yuchen
    Zhou, Wenjia
    Wang, Meng
    Zhang, Quanying
    Su, Mei
    Pan, Jie
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 196
  • [48] The JAK1-Selective Inhibitor GLPG0634 Is Safe and Rapidly Reduces Disease Activity In Patients With Moderate To Severe Rheumatoid Arthritis; Results Of a 4-Week Dose Ranging Study
    Tasset, Chantal
    Harrison, Pille
    Van der Aa, Annegret
    Meuleners, Luc
    Vanhoutte, Frederic
    van 't Klooster, Gerben
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1018 - S1018
  • [49] Infectious Bronchitis Virus Nsp14 Degrades JAK1 to Inhibit the JAK-STAT Signaling Pathway in HD11 Cells
    Ma, Peng
    Gu, Kui
    Li, Hao
    Zhao, Yu
    Li, Chao
    Wen, Renqiao
    Zhou, Changyu
    Lei, Changwei
    Yang, Xin
    Wang, Hongning
    VIRUSES-BASEL, 2022, 14 (05):
  • [50] Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
    Westhovens, R.
    Taylor, P. C.
    Alten, R.
    Pavlova, D.
    Enriquez-Sosa, F.
    Mazur, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 998 - 1008
12345